Maraganore John's Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Nov 12, 2021
- Accession no.
- 0001735276-21-000089
- Filed
- Nov 12, 2021
- Trade date
- Nov 12, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.83M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maraganore JohnCIK 0001180432 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | Common Stock | MOption exerciseAcquired | +33,978 | $7.10 | +$241,243.8 | 248,743 | Direct | |
| Nov 12, 2021 | Common Stock | SSaleDisposed | −10,365 | $170.36F2 | −$1,765,781.4 | 238,378 | Direct | |
| Nov 12, 2021 | Common Stock | SSaleDisposed | −7,742 | $171.35F3 | −$1,326,591.7 | 230,636 | Direct | |
| Nov 12, 2021 | Common Stock | SSaleDisposed | −14,518 | $172.22F4 | −$2,500,289.96 | 216,118 | Direct | |
| Nov 12, 2021 | Common Stock | SSaleDisposed | −683 | $173.25F5 | −$118,329.75 | 215,435 | Direct | |
| Nov 12, 2021 | Common Stock | SSaleDisposed | −670 | $174.34F6 | −$116,807.8 | 214,765 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | Common Stock | MOption exerciseDisposed | −33,978 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Sale prices ranged from $169.84 to $170.84.
Referenced by the price of 1 transaction in Table I.
- F3
Sale prices ranged from $170.85 to $171.82.
Referenced by the price of 1 transaction in Table I.
- F4
Sale prices ranged from $171.86 to $172.84.
Referenced by the price of 1 transaction in Table I.
- F5
Sale prices ranged from $172.90 to $173.34.
Referenced by the price of 1 transaction in Table I.
- F6
Sale prices ranged from $174.05 to $174.63.
Referenced by the price of 1 transaction in Table I.